within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BX04_SimvastatinAcetylsalicylicAcidAndRamipril;

model SimvastatinAcetylsalicylicAcidAndRamipril
  extends Pharmacolibrary.Drugs.ATC.C.C10BX04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10BX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination medication containing simvastatin (a statin for lowering cholesterol), acetylsalicylic acid (aspirin, for antiplatelet action), and ramipril (an ACE inhibitor for hypertension). It is indicated for cardiovascular prevention in patients at risk for or with established cardiovascular disease. While fixed-dose combinations like this have been researched, their commercial use and regulatory approval may be regionally limited.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies of the combined fixed-dose formulation; parameters here are estimated based on known individual drug PK in healthy adults after oral administration.</p><h4>References</h4><ol><li><p>Patel, A, et al., &amp; Chakraborty, BS (2010). Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. <i>American journal of cardiovascular drugs : drugs, devices, and other interventions</i> 10(2) 95â€“103. DOI:<a href=&quot;https://doi.org/10.2165/11532170-000000000-00000&quot;>10.2165/11532170-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20334446/&quot;>https://pubmed.ncbi.nlm.nih.gov/20334446</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end SimvastatinAcetylsalicylicAcidAndRamipril;
